Albany, NY -- (SBWIRE) -- 07/29/2019 -- Chronic Spinal Cord Injury Market Insights, Epidemiology and Market Forecast-2028
1. Spinal cord injury affects over 40,000 people in the UK and approximately 288,000 in the US.
2. An estimated 17,700 new cases of spinal cord injury in the US are recorded each year.
3. Around the world, between 250,000 and 500,000 people suffer a spinal cord injury every year.
DelveInsight launched a new report on Chronic Spinal Cord Injury Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Chronic Spinal Cord Injury market report covers a descriptive overview and comprehensive insight of the Chronic Spinal Cord Injury Epidemiology and Chronic Spinal Cord Injury market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Chronic Spinal Cord Injury market report provides insights into the current and emerging therapies.
3. Chronic Spinal Cord Injury market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Chronic Spinal Cord Injury market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Spinal Cord Injury market.
Request for sample pages
"Males are mostly at risk in young adulthood (20–29 years) and older age (70+). Females are likely to be at risk in adolescence (15–19) and older age (60+). Studies report male-to-female ratios of at least 2:1 among adults, sometimes much higher."
The first-line care of a patient with Spinal cord injury involves securing the airway, breathing, and circulation followed by appropriate spinal immobilization in the field to limit further insult of the highly susceptible cord during transport. Recognition and appropriate triage of Spinal cord injury patients are critical in the early period to ensure timely delivery of interventions at specialized centres. There is currently a lack the optimal approach to several areas of Spinal cord injury diagnosis and Spinal cord injury treatment, in part owing to heterogeneity in injuries (cervical versus thoracic, complete versus incomplete), but also owing to conflicting interpretations of the literature.
While maintaining spinal immobilization, airway and breathing management can range from supplemental oxygen to intubation and ventilation. At any point during the acute injury, systemic hypotension (systolic blood pressure [SBP] <90 mmHg) is associated with worse neurologic outcomes. With a profound loss of vascular tone and potential bradycardia, patients can rapidly fall into neurogenic shock. Large-volume intravenous (IV) fluid therapy (most often crystalloids) is the mainstay of treatment; however, adjunctive alpha-adrenergic vasopressors (e.g. norepinephrine and phenylephrine) may also be used to temporize patients.
Extensive research and development activities of pharmaceutical companies to develop the therapies for Chronic Spinal Cord Injury will create a positive impact on Chronic Spinal Cord Injury market during the forecast period (2019–2028).
Other factors that shall further expedite the growth of Chronic Spinal Cord Injury market during the forecast period (2019–2028) include increased morbidity rate and increasing awareness about available Chronic Spinal Cord Injury treatments.
The launch of the emerging therapies is expected to significantly impact Chronic Spinal Cord Injury treatment scenario in the upcoming years:-
Drugs covered
1. AXER-204
2. Cellgram-spine
3. NSI-566
And many others
The key players in Chronic Spinal Cord Injury market are:
1. ReNetX Bio
2. Pharmicell
3. Neuralstem
And many others
Table of contents
1. Report Introduction
2. Chronic Spinal Cord Injury Market Overview at a Glance
3. Chronic Spinal Cord Injury Disease Background and Overview
4. Chronic Spinal Cord Injury Epidemiology and Patient Population
5. Chronic Spinal Cord Injury Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1.Germany
5.2.4.Spain
5.2.5.United Kingdom
5.3. Japan
6. Chronic Spinal Cord Injury Treatment & Medical Practices
7. Chronic Spinal Cord Injury Key Emerging Therapies
7.1. AXER-204: ReNetX Bio
7.2. NSI-566: Neuralstem
8. Chronic Spinal Cord Injury Market Size
8.1. Key Findings
8.2. Total 7MM Chronic Spinal Cord Injury Market Analysis
9. Chronic Spinal Cord Injury Country-Wise Market Analysis 7MM
9.1. United States
9.2. Germany
9.3. France
9.4. United Kingdom
9.5. Spain
9.6. Italy
9.7. Japan
10. Market Drivers
11. Market Barriers
12. Appendix
13. Report Methodology
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight